Replies to post #125921 on Biotech Values

[NP1986]

Just a note of caution - complete responses do occur with single-agent gemcitabine (albeit rarely), so if you have a patient on gemcitabine + vismodegib who has a complete response, you cannot be certain that it was due to vismodegib.

[mcbio]

BTW, there is a slide in that video (1:09) which specifically references the Hh drug (and I am pretty sure the only Hh drug that is participating in the Stand Up to Cancer trials is Roche's GDC0449 aka Vismodegib)

I would just add that it strikes me as odd that these individuals would be discussing preliminary non-public trial results, even if they are being somewhat vague, in a YouTube video before the completion of the trials. I guess this makes the results public to some degree, but I would think that Roche and CRIS, or any other companies whose drugs are being referred to, would not want them to be discussing the preliminary results publically.

Separately, do you know when the pancreatic results are due for CRIS' hedgehog inhibitor?

[heldnova]

BioTechHedge I found only 1 patient in the blogs with pancreatic cancer who is in the CRIS trial. She had a 52% shrinkage in the primary tumor and near disappearance of the liver mets. This is a spectacular result but only 1 patient. Have you found more than 1 or 2 patients who are getting a good result?

Rick